KEAP1
Kelch-like ECH-associated protein 1
As of the edition of 20 October 2026, KEAP1 (kelch-like ECH-associated protein 1, UniProt Q14145) has 4 drugs tested at it and 4 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14145
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 121
- Disease areas
- Immune system; Nervous system; Pregnancy and women's health; Urinary and reproductive; Hormones; Nutrition and metabolism; Heart and blood vessels; Cancer
- Registered trials of its drugs
- 129
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dimethyl fumarate | Marketed | Phase 4 | none listed |
| Bardoxolone methyl | Stopped | Phase 3 | none listed |
| Diroximel fumarate | Marketed | Phase 3 | Ends 2033 |
| Monomethyl fumarate | Marketed | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Banner Life Sciences | Route B |
The other 3 companies at KEAP1
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at KEAP1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.